Oxford-AstraZeneca vaccine trials would be over by January ; Adar Poonawala

▴ Oxford-AstraZeneca vaccine trials would be over by January ; Adar Poonawala

Oxford and AstraZeneca’s Covid-19 vaccine trials in India are expected to be over by January, said Serum Institute of India (SII) CEO Adar Poonawalla. Speaking to India Today TV, Poonawalla said that the vaccine trials in India will be completed by January, adding that the first dose has been given to most of the people who took part in the trial.

Sharing details of the final stage of trial for the Oxford-AstraZeneca’s Covid-19 vaccine in India, Poonawalla said, “We have already given the first dose to most of the patients in the trial, which is more than a 1,000 already. The total trial is for 1,600 patients in India. Then we will give the second dose and then and then analyse them for safety and efficacy.”

“That’s why I say January to be absolutely safe for India. Then again, we have to wait till all the data comes in from the UK to collate that together and then the Indian drug controller will have enough data to decide which way to go and when to license the product,” he added.

Adar Poonawalla also said that Oxford’s vaccine is producing a good immune response in addition to antibodies.

“The data is very good. If the UK goes into emergency licensure, it will be up to the government of India to then decide and take a call after analysing that data to determine whether we follow suit in about a month as well,” he said.

“Having said that, our own trial in India will be completed by January. So now it will be up to the UK health authorities and the Indian health authorities to take a decision on how safe and effective this vaccine is.”

Story Credit > www.ndtv.com 

Tags : #OxfordVaccine #AstraZenecaVaccine #SerumInstituteOfIndia #AdarPoonawala #LatestVaccineNewsOct30

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Worldwide EndoMarch, Endo Run to raise mass awareness on Endometriosis!February 21, 2024
Uptick In Respiratory, and Cardiac Problems Due To Poor Air Quality In DelhiFebruary 21, 2024
Evidence shows risks associated with energy drinks in childrenFebruary 21, 2024
iHub-Data at IT-Hyderabad announces collaborative initiative with technical institutions for AI/ML training programsFebruary 20, 2024
Viatris Receives Global Minimized Risk of Antimicrobial Resistance Certification, Advancing its Commitment to Responsible Antibiotic ProductionFebruary 20, 2024
“Kusum Ka Biyaah” Indian Hindi film based on a true story releasing on 1st March 2024February 19, 2024
Introducing Moscow's Pioneering Initiative: An Open Dataset for AI-driven Brain Disease Detection"February 19, 2024
ICPA Health Products Introduces Coolora Spray - A Rapid Relief Solution For Oral & Throat DiscomfortFebruary 19, 2024
Section 43B of the Income Tax demystifiedFebruary 16, 2024
Nutricircle Introduces Health Supplements My45NutrientsTM to Enhance Overall Well-beingFebruary 16, 2024
YFLO organised a session “Design Your Story” to inspire young FICCI Ladies to design their own compelling storiesFebruary 15, 2024
149 experts call to find all TB to stop TBFebruary 15, 2024
ICPA Welcomes Global Leader In Periodontal Aesthetics - Prof Giovanni Zucchelli On His Inaugural Visit To IndiaFebruary 14, 2024
Fast Fashion and Sustainability are not friends and do not go well with each other: Namrata Joshipura, one of India’s most celebrated Fashion designers February 14, 2024
YFLO to organise a session Design Your StoryFebruary 14, 2024
Starkey Launches Genesis AI Hearing Aids in India, Pioneering a New Era in Hearing HealthFebruary 14, 2024
Indian Institute of Heritage and University of Birmingham announce strategic partnershipFebruary 14, 2024
Siddharth Anand’s Fighter emerges as the first hit of 2024February 13, 2024
India’s 26 years old youth’s Adventurous Atal Yatra to Celebrate Silver Jubilee of the Golden Quadrilateral beginsFebruary 13, 2024
Vitafoods India 2024 - Exploring Nutraceutical FrontiersFebruary 13, 2024